Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Idraparinux – Investigational Agent for Treatment and Prevention of Thromboembolic Events

PERSIST, a Phase II dose-ranging study was completed in 2002.

Go Top